Controlled trial – Page 30 – Communicable Diseases Research

A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam

Study Protocol

Published on 2020-06-122022-10-28
Journal: Wellcome Open Research [Category] COVID-19,

Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 A-a gradient acute lung injury acute respiratory distress addition allergic reaction alveolar macrophage alveolar pressure antiviral immunity Antwerp ARDS Belgium blinded Breastfeeding Bruges carbonate clinical clinician Confirmed COVID-19 infection control group Controlled trial COVID-19 COVID-19 pandemic defined Delta dissemination Effect element enrolled enrolment EudraCT ferritin level Ghent GM-CSF granulocyte-macrophage colony-stimulating factor High dose hospital Hypothesis hypoxic failure hypoxic respiratory failure Immune homeostasis inflammatory monocyte Inhaled Intervention intravenous invasive mechanical IWRS system leukine® lung malignancy mechanical ventilation mechanical ventilator Methylprednisolone number objective Open-label outcome oxygen Oxygenation paO2/fiO2 parameters Partial participant Participants Patient PF ratio pregnant primary endpoint progression of disease promote Protein protocol randomised randomised controlled trial randomization Randomized reached receive recruitment Registered Repair mechanisms replaced Respiratory failure Roeselare Sample size sargramostim SpO2 standard care Standard of care status Study protocol supplemental oxygen Support syndrome therapy treat Treatment Trial university ventilatory support Version website were excluded White blood cell
[DOI] 10.1186/s13063-020-04451-7 PMC 바로가기 [Article Type] Letter

Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 95% CI absence addition administration of hydroxychloroquine Admission aerosol-generating procedures allergy analyzed Anesthesia antibody approved ARMS assigned balanced randomization blind Cancer Cantabria carried CDC Cell Chemoprophylaxis clinical Clinical data clinically coated Committee comparator Comparator group computer-generated control group Controlled Controlled clinical trial Controlled trial coronavirus COVID COVID-19 criteria CURB current detect Determination disease dissemination double blind double-blind dropout rate Efficacy Efficacy and safety element ELISA kit Emergency Endocrine estimate Ethics Euroimmun Evidence evidence of Germany GRADE greater group Health Health authority health-care healthcare personnel Healthcare professional healthcare professionals heart heart failure help hematological high risk hospital Hydroxychloroquine hydroxychloroquine sulfate hygiene Hypothesis ICU IDT IgA IgG IgM and IgG immune immunodeficiency in vitro incidence include Infection inhibit intensive care unit Intervention investigator kidney lactation liver measure Measures Medicine Negative PCR neurological New York number observation period outcome participant PCR performed Personal protective equipment Placebo positive positive SARS-CoV-2 PCR positive serology Pregnancy presenting Prevalence Primary outcome probes product professional Prophylaxis Prospective PROTECT Protective protocol Psychiatric randomised randomised controlled trial randomization Randomized randomized trial RCT receive recruitment reduce reported responsible risk RT-PCR Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR sequence Seroconversion serological serology severity Significant single center single-center study social distancing Spain Spanish Standard Statistical power status Study protocol subject Support Symptom symptomatic and asymptomatic Tablet Takara Taking Tamoxifen Transmission Treatment two-tailed university Vaccine virus website while
[DOI] 10.1186/s13063-020-04400-4 PMC 바로가기 [Article Type] Letter

A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 age analogue anticipated assigned Asymptomatic blinded bpm Characteristics clinical trial comparator components Contact Controlled trial coronavirus disease COVID-19 COVID-19 symptom COVID19 Date deficiency develop Diabetes Mellitus Diagnosis disease dissemination dose double-blind drug Efficacy Efficiency eight element enrolled enrolment EU Clinical Trial evaluate evaluate the effect exclusion criteria experimental arm female participant Final Glucose haloperidol healthcare healthcare worker Healthcare workers hematological Hemodialysis hepatitis B Hereditary high risk history HIV HIV infection hospital hypersensitivity IgM/IgG immune immunosuppressive incidence Inclusion Infection Inflammatory cytokine Intervention less lymphopenia male melatonin men and women multicenter myasthenia gravis number objective outcome participant Patient PCR Placebo polymerase chain post-symptom onset Premenopausal Prevent prophylactic treatment Prophylaxis protocol Ramón randomisation randomised randomised controlled trial randomization Randomized Rapid test receiving recruited renal failure Research Retinitis rheumatoid arthritis risk RT-PCR Sample size SARS-CoV 2 SARS-CoV-2 SARS-COV-2 infection SAS version 9.4 secondary sequence Seroconversion severe COVID-19 severity of COVID-19 Sex Spain Spanish statistical status stratified study drug Study protocol symptomatic infection symptomatic SARS-CoV-2 infection Treatment Trial two-arm parallel ulcerative colitis understanding urinary pregnancy test Vasculitis website weight women
[DOI] 10.1186/s13063-020-04436-6 PMC 바로가기 [Article Type] Letter

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 active malignancy acute respiratory distress syndrome Administered administration age approval approved ARDS assessment automated Berlin blinded Cell cell suspension cellular changes in chronic liver disease class clinical Clinical diagnosis Clinical outcome clinical outcomes clinical trial comparator Compliance conducted control group Controlled trial COVID 19 COVID-19 COVID-19 pandemic declined defined described determine diagnosis of COVID-19 dissemination Donor Dose escalation driving Effect Efficacy element eligible Elizabeth enrolled ethics committee EudraCT excluded facilitate failure fixed dose hospital ICU incidence Inclusion increase in index individual information infusion intensive care unit Intervention Invasive mechanical ventilation investigator King’s College London London Mesenchymal stem cells Mesenchymal stromal cells MHRA moderate Mortality MSC MSCs NIHR number objective open label Other outcome pandemic PaO participant Patient patient population patients with ARDS PCR test PF ratio Phase 1 Phase 2 Placebo placebo-controlled protocol protocol amendment Public randomised randomised controlled trial REC receiving recruited recruitment repair reported Research respiratory Resuscitation Sample size secondary Secondary objective Secondary outcomes Serious Adverse Events severe ARDS single intravenous infusion SOFA solution Standard steering committee stratified stromal cell Study protocol Therapeutics therapy trauma Treatment Trial triple blinded Trust umbilical United Kingdom university Venous Thromboembolism Ventilation verbal Volume web-based randomisation system website WHO Withdrawal
[DOI] 10.1186/s13063-020-04416-w PMC 바로가기 [Article Type] Letter

The association between treatment with heparin and survival in patients with Covid-19

Article

Published on 2020-05-312022-10-30
Journal: Journal of Thrombosis and Thrombolysis [Category] Coronavirus, MERS,

Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Review

Published on 2020-05-232022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] 95% CI 95% confidence interval adverse event calculated caused CIs Combined therapy complementary and alternative medicine Controlled Controlled trial coronavirus disease cough COVID-19 data extraction database Effect effect size effective Effectiveness eligible evaluate fatigue Fever Herbal herbal medicine independent Medicine Odds ratio outbreak pandemic Patient performed RCT RCTs reported Respiratory illness review risk of bia risk ratio RRs searched Serious Adverse Event Significant significantly sore throat sputum production Symptom syndrome systematic review TCM treating COVID-19 Treatment Trial was used
[DOI] 10.3390/jcm9051583 PMC 바로가기 [Article Type] Review

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial

경증/중등도의 COVID-19 성인 환자에 대한 로피나비르/리토나비르 또는 아르비돌의 효능 및 안전성: 탐색적 무작위 대조 시험

Randomized Controlled Trial

Published on 2020-05-192022-09-14
Journal: Med (New York, N.Y.) [Category] SARS, 임상, 진단, 치료제,

[키워드] adverse event affected antiviral medication approved Arbidol assigned benefit caused Characteristics Chest computed tomography clinical Clinical outcome clinical status clinician comparable Context control group Controlled Controlled trial coronavirus SARS-CoV-2 cough COVID-19 COVID-19 pandemic Deterioration drug effective Efficacy Efficacy and safety enrolled exploratory finding follow-up period funding global pandemic group Guangzhou HIV-1 IMPROVE Influenza Lopinavir/ritonavir Mild moderate Moderate COVID-19 monotherapy no difference novel coronavirus SARS-CoV-2 occurred pathogen Patient patients hospitalized primary endpoint Randomized Randomly receive Respiratory illness responsible Safety SARS-CoV-2 SARS-CoV-2 nucleic acid Scientific community Secondary endpoints Significance standard care supported supportive care tested the disease therapy three group Treatment university virus
[DOI] 10.1016/j.medj.2020.04.001 PMC 바로가기 [Article Type] Randomized Controlled Trial

TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy

TAILoR(인간 면역결핍 바이러스[HIV]의 TelmisArtan 및 InsuLin 내성): 복합 항레트로바이러스 요법을 받는 HIV 양성 환자의 인슐린 내성 감소를 위한 Telmisartan의 적응형 설계, 용량 범위 IIb상 무작위 시험

Articles and Commentaries

Published on 2020-05-152022-09-06
Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease,

[키워드] adaptive Analysis antiretroviral drugs Antiretroviral therapy Antiretrovirals ARMS cardiovascular disease check clinical Combination conducted Controlled trial demonstrated Efficacy evaluated fat had no HIV HIV infection homeostasis Human Human immunodeficiency virus identify IIb immunodeficiency virus improvement Improvements index individual Infection insulin insulin resistance Insulin sensitivity interim analysis Intervention investigated ISRCTN liver longitudinal longitudinal analysis measure metabolic abnormalities Metabolic abnormality metabolic disease morbidity and mortality multicenter no difference no differences no significant effect once daily Open-label participant Patient phase plasma Primary outcome primary outcome measure Randomized receiving recruited reduce reduction in Registration resistance Result risk secondary outcome measures significant effect Stage stage II telmisartan Trial with HIV
[DOI] 10.1093/cid/ciz589 PMC 바로가기 [Article Type] Articles and Commentaries

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

주로 경증에서 중등도의 코로나바이러스 질환 환자의 하이드록시클로로퀸 2019: 공개 라벨, 무작위 대조 시험

Research

Published on 2020-05-142022-08-09
Journal: The BMJ [Category] Fulltext, MERS, 임상,

[키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse adverse event adverse events analysed Analysis assigned China Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 covid-19 treatment centre diarrhoea dose Efficacy and safety event followed by Government group hospital Hydroxychloroquine hydroxychloroquine group hydroxychloroquine non-recipient hydroxychloroquine non-recipients hydroxychloroquine recipient hydroxychloroquine recipients Intention intention to treat laboratory confirmed covid-19 Loading dose maintenance dose Mild mild to moderate mild to moderate disease moderate moderate disease negative Negative conversion non-recipients objective open open label outcome measure participant Patient patients principle Probability randomisation randomised controlled trial recipients reported respiratory Result safety population Serious Adverse Events setting severe acute respiratory syndrome Coronavirus severe disease significantly higher Standard of care symptom onset Treatment Trial registration virus were recorded
[DOI] 10.1136/bmj.m1849 PMC 바로가기 [Article Type] Research